Terry J. Fry, M.D.
Terry J. Fry, M.D.
Investigator
Head, Hematologic Malignancies Section

Dr. Terry Fry heads the Hematologic Malignancies Section in the Pediatric Oncology Branch. His research is focused on the preclinical and clinical development of cell-based immunotherapy for pediatric leukemias. He is actively engaged in national cooperative groups involved in improving outcomes following hematopoietic stem cell transplantation for pediatric malignancies. More recently, his efforts have also focused on the use of genetically modified T cell therapy for acute lymphoblastic leukemia.

Areas of Expertise
1) pediatric leukemia, 2) hematopoietic stem cell transplantation, 3) immunotherapy, 4) adoptive cell therapy

Contact Info

Terry J. Fry, M.D.
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 2-3942
Bethesda, MD 20892-1104
301-402-0215
fryt@mail.nih.gov
Link to Clinicaltrials.gov Protocol ID Referral Phone

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies

NCI-15-C-0029 1-877-624-4878

Hematologic Malignancy Biology Study

NCI-04-C-0102 1-877-624-4878

Hematologic Malignancies Section

Despite substantial improvements in outcome over the past 3 decades, leukemia remains the leading cause of cancer-related mortality in children.  Furthermore, even in patients cured by modern risk-adapted therapy, there are substantial long-term sequelae. Thus, newer treatments are needed, particularly those not based on standard cytotoxic agents.  The Hematologic Malignancies Section (HMS) conducts lab-based translational research focused on immunotherapeutic approaches for leukemia.  Clinical efforts in the treatment of leukemia occur within the Pediatric Oncology Branch (POB) clinical program where early phase clinical trials are conducted. Studies in immunotherapy for leukemia in the HMS were initially grounded in the optimization of the graft versus leukemia effect that contributes to the curative potential of hematopoietic stem cell transplantation (HSCT) for hematologic malignancies.  Much of the work currently taking place in the HMS and in the POB clinical program is now focused on the use of cell-based immunotherapy for pediatric leukemia outside of the HSCT setting as well as more basic studies in leukemia biology related to the bone marrow microenvironment and immune escape.  In a particular, the HMS is now heavily focused on the use of genetically modified T cells expressing chimeric antigen receptors (CAR) for the treatment of pediatric acute lymphoblastic leukemia.  Initial early phase clinical studies using a CD19-targeted CAR in patients with pre-B cell acute lymphoblastic leukemia (ALL), including a trial conducted in the Branch, have demonstrated a 70-80% complete remission rate. However, not all patients respond and approximately 10% of patients will relapse with leukemia that loses the CD19 epitope targeted by the CAR.  

Aim 1:  Translational development of chimeric antigen receptors for the treatment of pediatric leukemia. Using in vitro studies and xenograft models of pediatric ALL in immune-deficient mice, the HMS has performed much of the preclinical optimization of a novel CD22-targeted CAR.  Dr. Fry will be leading the first-in-human clinical trial using this CAR in children and young adults with relapsed and refractory pre-B cell ALL.  The HMS has also developed 2 other CAR constructs that target antigens expressed on pre-B cell ALL that will likely enter clinical trials in the near future.  Finally, the HMS is extending CAR therapy to other forms of pediatric leukemia including acute myelogenous leukemia and T cell ALL.

Aim 2:  Elucidation of the biologic principles involved in the immunotherapeutic targeting of pediatric leukemia.  The HMS utilizes a novel syngeneic murine model of CAR therapy for pre-B cell ALL that is being used to study in vivo biology of CAR therapy in an immunologically intact system.  Collectively, these studies have provided an opportunity to study immunotherapeutic resistance of ALL to CAR T cells.  Finally, using these syngeneic murine ALL models, the HMS is conducting studies on the role the bone marrow microenvironment plays in immunotherapeutic resistance.

Scientific Focus Areas:
Cancer Biology, Clinical Research, Immunology

View Dr. Fry's PubMed Summary.

Selected Recent Publications
  1. Capitini CM, Nasholm NM, Chien CD, Larabee SM, Qin H, Song YK, Klover PJ, Hennighausen L, Khan J, Fry TJ.
    Blood. 24: 11976-86., 2014. [ Journal Article ]
  2. Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ.
    Biol. Blood Marrow Transplant. 20: 26-36, 2014. [ Journal Article ]
  3. Capitini CM, Nasholm NM, Duncan BB, Guimond M, Fry TJ.
    J Immunol. 190: 1351-9, 2013. [ Journal Article ]
  4. Fry TJ, Mackall CL.
    Hematology Am Soc Hematol Educ Program. 2013: 348-53, 2013. [ Journal Article ]
  5. Mackall CL, Merchant MS, Fry TJ.
    Nat Rev Clin Oncol. 11: 693-703, 2014. [ Journal Article ]

Terry J. Fry received a B.A. from Colgate University in 1988 and M.D. from Georgetown University in 1992. After completing Pediatric Residency at Georgetown in 1995, he served as Chief Pediatric Resident. From 1996-1999 Dr. Fry undertook fellowship training in Pediatric Hematology and Oncology at Johns Hopkins University. In 1997, during the research component of his fellowship training, he began working in the laboratory of Dr. Crystal Mackall first as a visiting fellow and subsequently as a post-doctoral fellow. He then became a Staff Clinician in the Pediatric Oncology Branch in 2004. In 2007, Dr. Fry became Chief of the Division of Blood and Marrow Transplantation at Children's National Medical Center, a position he held until 2010 when he returned to the Pediatric Oncology Branch as an Investigator. He is a member of multiple societies including the American Society of Hematology, the American Association of Immunology and the American Society of Blood and Marrow Transplantation. He also serves as Chair of the Oncology Strategy Group in the Pediatric Blood and Marrow Transplant Consortium and is a member of the Stem Cell Transplantation Committee in Children's Oncology Group.

Name Position
Fidelia Acevedo Program Assistant
Christopher Chien Ph.D. Postdoctoral Fellow (CRTA)
Elad Jacoby M.D. Clinical Fellow
Ekta Kapadia M.D. Special Volunteer
Sang Nguyen B.S. Postbaccalaureate Fellow
Haiying Qin M.S. Research Biologist
Haneen Shalabi M.D. Special Volunteer
Yinmeng Yang Predoctoral Fellow
Bonnie Yates RN Nurse Specialist

Clinical Trials

Link to Clinicaltrials.gov Protocol ID Referral Phone

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies

NCI-15-C-0029 1-877-624-4878

Hematologic Malignancy Biology Study

NCI-04-C-0102 1-877-624-4878

Research

Hematologic Malignancies Section

Despite substantial improvements in outcome over the past 3 decades, leukemia remains the leading cause of cancer-related mortality in children.  Furthermore, even in patients cured by modern risk-adapted therapy, there are substantial long-term sequelae. Thus, newer treatments are needed, particularly those not based on standard cytotoxic agents.  The Hematologic Malignancies Section (HMS) conducts lab-based translational research focused on immunotherapeutic approaches for leukemia.  Clinical efforts in the treatment of leukemia occur within the Pediatric Oncology Branch (POB) clinical program where early phase clinical trials are conducted. Studies in immunotherapy for leukemia in the HMS were initially grounded in the optimization of the graft versus leukemia effect that contributes to the curative potential of hematopoietic stem cell transplantation (HSCT) for hematologic malignancies.  Much of the work currently taking place in the HMS and in the POB clinical program is now focused on the use of cell-based immunotherapy for pediatric leukemia outside of the HSCT setting as well as more basic studies in leukemia biology related to the bone marrow microenvironment and immune escape.  In a particular, the HMS is now heavily focused on the use of genetically modified T cells expressing chimeric antigen receptors (CAR) for the treatment of pediatric acute lymphoblastic leukemia.  Initial early phase clinical studies using a CD19-targeted CAR in patients with pre-B cell acute lymphoblastic leukemia (ALL), including a trial conducted in the Branch, have demonstrated a 70-80% complete remission rate. However, not all patients respond and approximately 10% of patients will relapse with leukemia that loses the CD19 epitope targeted by the CAR.  

Aim 1:  Translational development of chimeric antigen receptors for the treatment of pediatric leukemia. Using in vitro studies and xenograft models of pediatric ALL in immune-deficient mice, the HMS has performed much of the preclinical optimization of a novel CD22-targeted CAR.  Dr. Fry will be leading the first-in-human clinical trial using this CAR in children and young adults with relapsed and refractory pre-B cell ALL.  The HMS has also developed 2 other CAR constructs that target antigens expressed on pre-B cell ALL that will likely enter clinical trials in the near future.  Finally, the HMS is extending CAR therapy to other forms of pediatric leukemia including acute myelogenous leukemia and T cell ALL.

Aim 2:  Elucidation of the biologic principles involved in the immunotherapeutic targeting of pediatric leukemia.  The HMS utilizes a novel syngeneic murine model of CAR therapy for pre-B cell ALL that is being used to study in vivo biology of CAR therapy in an immunologically intact system.  Collectively, these studies have provided an opportunity to study immunotherapeutic resistance of ALL to CAR T cells.  Finally, using these syngeneic murine ALL models, the HMS is conducting studies on the role the bone marrow microenvironment plays in immunotherapeutic resistance.

Scientific Focus Areas:
Cancer Biology, Clinical Research, Immunology

Publications

View Dr. Fry's PubMed Summary.

Selected Recent Publications
  1. Capitini CM, Nasholm NM, Chien CD, Larabee SM, Qin H, Song YK, Klover PJ, Hennighausen L, Khan J, Fry TJ.
    Blood. 24: 11976-86., 2014. [ Journal Article ]
  2. Shand JC, Qin H, Nasholm N, Capitini CM, Fry TJ.
    Biol. Blood Marrow Transplant. 20: 26-36, 2014. [ Journal Article ]
  3. Capitini CM, Nasholm NM, Duncan BB, Guimond M, Fry TJ.
    J Immunol. 190: 1351-9, 2013. [ Journal Article ]
  4. Fry TJ, Mackall CL.
    Hematology Am Soc Hematol Educ Program. 2013: 348-53, 2013. [ Journal Article ]
  5. Mackall CL, Merchant MS, Fry TJ.
    Nat Rev Clin Oncol. 11: 693-703, 2014. [ Journal Article ]

Biography

Terry J. Fry received a B.A. from Colgate University in 1988 and M.D. from Georgetown University in 1992. After completing Pediatric Residency at Georgetown in 1995, he served as Chief Pediatric Resident. From 1996-1999 Dr. Fry undertook fellowship training in Pediatric Hematology and Oncology at Johns Hopkins University. In 1997, during the research component of his fellowship training, he began working in the laboratory of Dr. Crystal Mackall first as a visiting fellow and subsequently as a post-doctoral fellow. He then became a Staff Clinician in the Pediatric Oncology Branch in 2004. In 2007, Dr. Fry became Chief of the Division of Blood and Marrow Transplantation at Children's National Medical Center, a position he held until 2010 when he returned to the Pediatric Oncology Branch as an Investigator. He is a member of multiple societies including the American Society of Hematology, the American Association of Immunology and the American Society of Blood and Marrow Transplantation. He also serves as Chair of the Oncology Strategy Group in the Pediatric Blood and Marrow Transplant Consortium and is a member of the Stem Cell Transplantation Committee in Children's Oncology Group.

Team

Name Position
Fidelia Acevedo Program Assistant
Christopher Chien Ph.D. Postdoctoral Fellow (CRTA)
Elad Jacoby M.D. Clinical Fellow
Ekta Kapadia M.D. Special Volunteer
Sang Nguyen B.S. Postbaccalaureate Fellow
Haiying Qin M.S. Research Biologist
Haneen Shalabi M.D. Special Volunteer
Yinmeng Yang Predoctoral Fellow
Bonnie Yates RN Nurse Specialist